Fortunately, understanding how they behave and what to do when they bleed can make managing them much easier
The 2026 EASO pharmacotherapy update formalised this evidence by ranking tirzepatide above semaglutide for obesity management, while simultaneously supporting semaglutide as the better-documented agent for liver fibrosis improvement in metabolic dysfunction-associated steatohepatitis (MASH), based on more mature phase 3 ESSENCE trial data [1]
Luo Y, Li Z, Ge P, Guo H, Li L, Zhang G, Xu C, Chen H
Detailed guidance on semaglutide fatigue and tirzepatide fatigue covers the full diagnostic framework
Medicare Discover an honest look at our Medicare system
Effects of polyphenol-rich, berry supplementation on exercise performance: a systematic review and meta-analysis